Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 2 | Breast Cancer Research

Figure 2

From: Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients

Figure 2

Mass spectra of germline TP53 mutations p. A138V (c. 413C > T) and p. E285K (c. 853G > A) for LOH analyses. (a) Loss of the wildtype C allele observed for sample extracted from FFPE breast cancer sample from BRC349 where 80% was tumor tissue (b) No LOH was observed for sample extracted from FFPE breast cancer sample from BRC873 where > 40% was tumor tissue. Left panel, control blood samples; Right panel, tumor samples; LOH, loss of heterozygosity.

Back to article page